Press "Enter" to skip to content

Morning Break: Rebranding Eating Disorders; Spike in Kratom Concerns; Vaccine Laws

Note that some links may require subscriptions.

Are high-profile advocates of “extreme fasting” merely rebranding eating disorders? (The Guardian)

Richard Sackler, MD, the former president of Purdue Pharma, embraced a plan to conceal the strength of OxyContin from physicians back in 1997, agreeing with the company’s head of sales that doing so would be “extremely dangerous at this early stage in the life of the product,” according to sealed testimony obtained by STAT News and ProPublica.

A triennial study found a modest drop in U.S. physician burnout in 2017, with 43.9% exhibiting at least one burnout symptom compared with 54.4% in 2014 and 45.5% in 2011. (Mayo Clinic Proceedings)

U.S. poison control center phones have lit up with a dramatic increase in calls about kratom exposures. (CBS News)

After her son died of an overdose, a woman in Delaware used social media to share a photo of her identifying the body at a morgue, hoping that it encourages others to “stop walking around blindly” about the opioid epidemic. (Fox News)

A Texas nurse created a public database of women killed by men, saying silence on the issue “is deafening.” (ABC News)

Google unveiled a locator tool in their maps app to identify authorized prescription drug disposal sites.

A measles epidemic in Madagascar has caused or contributed to 900 deaths since last September, most of whom were young children. (NBC News)

Meanwhile, YouTube continues to promote anti-vaccine videos. (BuzzFeed)

If states don’t fix loopholes in vaccination laws, FDA Commissioner Scott Gottlieb, MD, said the feds may step in. (CNN)

Catalyst Pharmaceuticals defended its $375,000 price tag for amifampridine (Firdapse), a new therapy for the rare neurological disorder Lambert-Eaton myasthenic syndrome, saying the price was in line with similar products. (Reuters)

Reflecting the dramatic growth of an emerging industry, on-demand food-delivery company DoorDash has a current estimated value of $7.1 billion. (Axios)

Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]

2019-02-22T09:30:00-0500

Source: MedicalNewsToday.com